Company intelligence / Profile preview

Clover

Shanghai, Shanghai, China

Ownership: Public · CLOV
Employees: ~300
Development stage: Other

Overview

Clover Biopharmaceuticals is a global, commercial-stage vaccine-focused biotech with integrated R&D, manufacturing, and commercialization capabilities. It has delivered authorized COVID-19 booster and quadrivalent influenza vaccines, with an RSV vaccine candidate in clinical development. Its pipeline targets infectious and non-communicable diseases using its proprietary Trimer-Tag platform

Therapeutic areas: OncologyInfectious DiseasesImmunology
Modalities: VaccineMonoclonal antibody
Industry: Biotech

Partnerships

COVAX (for COVID-19 vaccine supply)Dynavax (adjuvant supplier for COVID-19 vaccine)

Beyond the preview

Go deeper on Clover.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clover.

Explore the full profile